http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Seelos Therapeutics (SEEL) Announces Proposed Public Offering of Common Stock
-
Seelos Therapeutics Announces Proposed Public Offering of Common Stock
-
Seelos Therapeutics (SEEL) Receives Notice of Allowance in Japan for SLS-005
-
Seelos Therapeutics Receives a Notice of Allowance in Japan for SLS-005 (Trehalose)
-
Seelos Therapeutics Announces Dosing of the First Patients in a Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
-
Seelos Therapeutics (SEEL) Announces Year End 2020 Business Update
-
Seelos Therapeutics Announces Year End 2020 Business Update
-
Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Seelos Therapeutics (SEEL) Announces Issuance of a Patent for Trehalose (SLS-005) in Israel
-
Seelos Therapeutics Announces Issuance of a Patent for Trehalose (SLS-005) in Israel
-
Seelos Therapeutics (SEEL) Announces Selection of SLS-005 for HEALEY ALS Platform Trial for Amyotrophic Lateral Sclerosis Led by Harvard Medical School
-
Seelos Therapeutics Announces the Selection of SLS-005 (Trehalose) for the HEALEY ALS Platform Trial for Amyotrophic Lateral Sclerosis Led by the Harvard Medical School
-
Seelos Therapeutics (SEEL) Raises $10 Million In Private Placement of Senior Secured Convertible Note
-
Seelos Therapeutics Raises $10 Million In Private Placement of Senior Secured Convertible Note
-
Seelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event
-
Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Seelos Therapeutics (SEEL) Granted U.S. Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis
-
Seelos Therapeutics Receives US Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis
-
Seelos Therapeutics to Participate in the 3rd International Conference on Sanfilippo Syndrome and Related Diseases
-
Seelos Therapeutics Announces Issuance of Composition of Matter Patent for SLS-007
-
Seelos Therapeutics to Participate in Investor Conferences in November
-
Seelos Therapeutics (SEEL) Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in Parkinson's Disease
-
Seelos Therapeutics Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in Parkinson's Disease
-
Seelos Therapeutics (SEEL) Announces Issuance of New Patent and Additional Notice of Allowance in Japan for Intranasal Racemic Ketamine (SLS-002)
-
Seelos Announces Issuance of a New Patent and an Additional Notice of Allowance in Japan for Intranasal Racemic Ketamine (SLS-002)
-
Seelos Therapeutics (SEEL) Receives Notice of Allowance for Additional US Patent for Trehalose
-
Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)
-
Seelos Therapeutics Announces Closing of $7.0 Million Registered Direct Offering
-
Seelos Therapeutics (SEEL) Prices 8.865M Share Registered Direct Offering at $0.79/Sh
-
Seelos Therapeutics Announces Pricing of $7.0 Million Registered Direct Offering
-
Seelos Therapeutics to Participate in the Cantor Virtual Global Healthcare Conference
-
Seelos Therapeutics (SEEL) Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome
-
Seelos Therapeutics Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome
-
Seelos Therapeutics (SEEL) Receives FDA May Proceed Notice to Initiate Phase IIb/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis
-
Seelos Therapeutics Receives FDA May Proceed Notice to Initiate a Phase IIb/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis
-
Seelos Therapeutics (SEEL) Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome
-
Seelos Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome
-
Seelos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Seelos Therapeutics (SEEL) Commences Preclinical Study of SLS-007 in Parkinson's Disease
-
Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-007 in Parkinson's Disease
-
Seelos Therapeutics (SEEL) Reports Final Data from Ph. I PK/PD Study of Intranasal Racemic Ketamine (SLS-002) and Clinical Development Plans
-
Seelos Therapeutics Announces Final Data from Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002) and Clinical Development Plans
-
Seelos Therapeutics to Host Key Opinion Leader Call to Discuss Phase I Data and Upcoming Trial Design for SLS-002
-
Seelos Therapeutics (SEEL) Commences Preclinical Study of SLS-004 in Parkinson’s Disease
-
Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinson’s Disease
-
Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinson’s Disease
-
Seelos Therapeutics to Host Key Opinion Leader Call to Discuss the Unmet Medical Needs in Suicide and Depression
-
Seelos Therapeutics to Host Key Opinion Leader Call to Discuss the Unmet Medical Needs in Suicide and Depression
-
Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference
